Crohn's Disease: Full Disease Coverage - Product Image

Crohn's Disease: Full Disease Coverage

  • ID: 4238685
  • Report
  • 315 Pages
  • Datamonitor Healthcare
1 of 3
The Number of Prevalent Cases of Crohn's Disease ss Expected to Increase by 16.9% to 1.6 Million over 2015-35
Disease Overview

Crohn’s disease involves inflammation of the gastrointestinal (GI) tract, and most commonly affects the terminal ileum or colon. Because Crohn’s disease can occur in various areas of the GI tract, disease activity and severity can vary widely over time, with symptoms ranging from mild to severe and depending on the location in the GI tract at which the disease is active. Crohn’s disease is a chronic, incurable disease with low mortality that is generally diagnosed in adolescence and early adulthood.

Market Snapshot
  • Stelara is set to become the leading brand in Crohn’s disease as the longstanding anti-TNFs face biosimilar competition.
  • Infliximab - Remicade and its biosimilar versions - remains the most frequently prescribed biologic by surveyed physicians.
  • Crohn’s disease is an expanding global health problem, with prevalent cases forecasted to increase in the majority of analyzed countries.
  • Gastroenterologists intend to prescribe Stelara over Entyvio due to its faster onset of action and comparable safety.
  • Mongersen’s oral formulation and favorable safety will drive prescribing, despite its overall modest efficacy to date.
Note: Product cover images may vary from those shown
2 of 3
FORECAST: CROHN’S DISEASE
Executive Summary
Market Overview and Trends
Market Definition and Methodology
Cimzia (certolizumab pegol)
Cx601
Entyvio (vedolizumab)
etrolizumab
filgotinib
Humira (adalimumab)
mongersen (GED 0301)
Remicade (infliximab)
Stelara (ustekinumab)
Tysabri (natalizumab)
Primary Research Methodology

TREATMENT: CROHN’S DISEASE
Executive Summary
Primary Research Methodology
Patient Segmentation
Current Treatment Options
Prescribing Trends
Compliance
Unmet Needs in Crohn’s Disease
Prescribing Influences
Impact of Biosimilars

EPIDEMIOLOGY: CROHN’S DISEASE
Executive Summary
Disease Background
Sources and Methodology
Forecast
Epidemiologist Insight
Strengths and Limitations
Appendix

MARKETED DRUGS: CROHN’S DISEASE
Executive Summary
Product Overview
Product profile: Cimzia
Product profile: Entyvio
Product profile: Humira
Product profile: Remicade
Product profile: Stelara
Product profile: Tysabri
PIPELINE: CROHN'S DISEASE
Executive Summary
Clinical Pipeline Overview
Comparator Therapy
Product profile (late stage): Cx601
Product profile (late stage): etrolizumab
Product profile (late stage): filgotinib
Product profile (late stage): mongersen

List of Figures
Figure 1: Crohn’s disease sales across the US, Japan, and five major EU markets, by country, 2016-25
Figure 2: Crohn’s disease sales across the US, Japan, and five major EU markets, by class, 2016-25
Figure 3: Sales of Humira, Remicade, and their biosimilar versions in the US, Japan, and five major EU markets, 2016-25
Figure 4: Sales of Stelara, key branded anti-TNFs, and Entyvio in the US, Japan, and five major EU markets, 2016-25
Figure 5: Forecast sales of late-phase therapies in Crohn’s disease across the US, Japan, and five major EU markets, 2016-25
Figure 6: The author’s Crohn’s disease forecast methodology
Figure 7: Price sources and calculations, by country
Figure 8: Cimzia sales in Crohn’s disease across the US, Japan, and Spain, by country, 2016-25
Figure 9: Cx601 sales in Crohn’s disease across the US and five major EU markets, by country, 2016-25
Figure 10: Entyvio sales in Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016-25
Figure 11: Etrolizumab sales in Crohn’s disease across the US and five major EU markets, by country, 2016-25
Figure 12: Filgotinib sales for Crohn’s disease in the US and five major EU markets, 2016-25
Figure 13: Humira sales in Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016-25
Figure 14: Mongersen sales in Crohn’s disease across the US and five major EU markets, by country, 2016-25
Figure 15: Remicade sales in Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016-25
Figure 16: Stelara sales in Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016-25
Figure 17: Tysabri sales in Crohn’s disease in the US, 2016-25
Figure 18: Severity of diagnosed Crohn’s disease patients, by country
Figure 19: Mean percentage of Crohn’s disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
Figure 20: Mean percentage use of systemic and non-systemic corticosteroids in the US, Japan, and five major EU markets, by line of therapy
Figure 21: Mean percentage of drug-treated Crohn’s disease patients receiving monotherapy versus combination therapy, by line of therapy
Figure 22: Mean percentage of drug-treated Crohn’s disease patients receiving anti-TNF therapy, by country and line of therapy
Figure 23: Mean percentage use of biologic therapies for the treatment of drug-treated Crohn’s disease patients, by biologic and line of therapy
Figure 24: Mean compliance rates for drug-treated Crohn’s disease patients, by formulation type
Figure 25: Top treatment challenges in Crohn’s disease
Figure 26: Summary of future usage of biosimilar infliximab at one year and three years post-launch
Figure 27: Physician confidence in prescribing biosimilars for Crohn’s disease approved on the basis of indication extrapolation, by country
Figure 28: Trends in diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2015-35
Figure 29: Absolute growth of diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2015-35
Figure 30: Male diagnosed prevalent Crohn’s disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
Figure 31: Female diagnosed prevalent Crohn’s disease cases in each age group in the US, Japan, and five major EU markets, by country, 2015
Figure 32: Drug assessment summary for Crohn’s disease
Figure 33: Cimzia for Crohn’s disease - SWOT analysis
Figure 34: Drug assessment summary of Cimzia in Crohn’s disease
Figure 35: Drug assessment summary of Cimzia in Crohn’s disease
Figure 36: Entyvio for Crohn’s disease - SWOT analysis
Figure 37: Drug assessment summary of Entyvio in Crohn’s disease
Figure 38: Drug assessment summary of Entyvio in Crohn’s disease
Figure 39: Humira for Crohn’s disease - SWOT analysis
Figure 40: Drug assessment summary of Humira in Crohn’s disease
Figure 41: Drug assessment summary of Humira in Crohn’s disease
Figure 42: Remicade for Crohn’s disease - SWOT analysis
Figure 43: Drug assessment summary of Remicade in Crohn’s disease
Figure 44: Drug assessment summary of Remicade in Crohn’s disease
Figure 45: Stelara for Crohn’s disease - SWOT analysis
Figure 46: Drug assessment summary of Stelara in Crohn’s disease
Figure 47: Drug assessment summary of Stelara in Crohn’s disease
Figure 48: Tysabri for Crohn’s disease - SWOT analysis
Figure 49: Drug assessment summary of Tysabri in Crohn’s disease
Figure 50: Drug assessment summary of Tysabri in Crohn’s disease
Figure 51: Cx601 for Crohn’s disease - SWOT analysis
Figure 52: Drug assessment summary of Cx601 in Crohn’s disease
Figure 53: Drug assessment summary of Cx601 in Crohn’s disease
Figure 54: Etrolizumab for Crohn’s disease - SWOT analysis
Figure 55: Drug assessment summary of etrolizumab in Crohn’s disease
Figure 56: Drug assessment summary of etrolizumab in Crohn’s disease
Figure 57: Filgotinib for Crohn’s disease - SWOT analysis
Figure 58: Drug assessment summary of filgotinib in Crohn’s disease
Figure 59: Drug assessment summary of filgotinib in Crohn’s disease
Figure 60: Mongersen for Crohn’s disease - SWOT analysis
Figure 61: Drug assessment summary of mongersen in Crohn’s disease
Figure 62: Drug assessment summary of mongersen in Crohn’s disease

List of Tables
Table 1: Summary of key classes and brands and molecules included in the author’s Crohn’s disease patientbased forecast
Table 2: Exchange rates used for calculating prices
Table 3: The author’s price assumptions for Cimzia
Table 4: Cimzia sales in Crohn’s disease across the US, Japan, and Spain, by country ($m), 2016-25
Table 5: Cx601 sales in Crohn’s disease across the US and five major EU markets, by country ($m), 2016-25
Table 6: The author’s price assumptions for Entyvio
Table 7: Entyvio sales in Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 8: Etrolizumab sales in Crohn’s disease across the US and five major EU markets, by country ($m), 2016-25
Table 9: Filgotinib sales in Crohn’s disease across the US and five major EU markets, by country ($m), 2016-25
Table 10: The author’s price assumptions for Humira
Table 11: Humira sales in Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 12: Mongersen sales in Crohn’s disease across the US and five major EU markets, by country ($m), 2016-25
Table 13: The author’s price assumptions for Remicade
Table 14: Remicade sales in Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 15: The author’s price assumptions for Stelara
Table 16: Stelara sales in Crohn’s disease across the US, Japan, and five major EU markets, by country ($m), 2016-25
Table 17: The author’s price assumptions for Tysabri
Table 18: Tysabri sales in Crohn’s disease in the US ($m), 2016-25
Table 19: Gastroenterologists surveyed for the Crohn’s disease primary research study, 2016
Table 20: Gastroenterologists surveyed for the Crohn’s disease primary research study, 2016
Table 21: Treatment guidelines: initial treatment of active Crohn’s disease, by severity
Table 22: Treatment guidelines: maintenance of medically induced remission of Crohn’s disease and other therapy recommendations
Table 23: Summary of key classes and products included in the author’s Crohn’s disease survey
Table 24: Crohn’s disease patients receiving pharmacological therapy or non-pharmacological therapy only, by country
Table 25: Mean percentage of drug-treated Crohn’s disease patients receiving each drug class, by line of therapy and country (%)
Table 26: Mean percentage of drug-treated Crohn’s disease patients receiving monotherapy or combination therapy, by line of therapy and country (%)
Table 27: Mean percentage of drug-treated Crohn’s disease patients receiving each biologic therapy, by line of therapy and country (%)
Table 28: Compliance rates for Crohn’s disease patients, by formulation type and country (%)
Table 29: Relative importance of treatment challenges in Crohn’s disease, by country
Table 30: Relative importance of factors that influence gastroenterologists’ prescription of biologics and aminosalicylates in Crohn’s disease, by country
Table 31: Initial usage of biosimilar infliximab, according to respondents using biosimilar infliximab at the time of the survey, by country (%)
Table 32: Expected usage of biosimilar infliximab, according to respondents who did not prescribe biosimilar infliximab at the time of the survey, by country (%)
Table 33: Inflammatory bowel disease risk factors
Table 34: Montreal classification of Crohn’s disease
Table 35: Sources used for Crohn’s disease analysis in the US, Japan, and five major EU markets
Table 36: Notable sources not used for Crohn’s disease analysis in the US, Japan, and five major EU markets
Table 37: Summary of Crohn’s disease data processing in the US, Japan, and five major EU markets
Table 38: Diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2015-35
Table 39: Age- and gender-specific diagnosed prevalent cases of Crohn’s disease in the US, Japan, and five major EU markets, by country, 2015
Table 40: Phenotypic distribution of Crohn’s disease at diagnosis, by Montreal classification and country, 2015
Table 41: Key marketed drugs for Crohn’s disease
Table 42: Cimzia drug profile
Table 43: Cimzia pivotal trial data in Crohn’s disease
Table 44: Cimzia late-phase trial data in Crohn’s disease
Table 45: Entyvio drug profile
Table 46: Entyvio pivotal trial data in Crohn’s disease
Table 47: Entyvio ongoing late-phase clinical trials in Crohn’s disease
Table 48: Humira drug profile
Table 49: Humira pivotal trial data in adult Crohn’s disease
Table 50: Humira pivotal trial data in pediatric Crohn’s disease
Table 51: Humira ongoing trials in Crohn’s disease
Table 52: Remicade drug profile
Table 53: Remicade pivotal trial data in adult Crohn’s disease
Table 54: Remicade pivotal trial data in pediatric Crohn’s disease
Table 55: Stelara drug profile
Table 56: Stelara pivotal trial data in Crohn’s disease
Table 57: Tysabri drug profile
Table 58: Tysabri pivotal trial data in Crohn’s disease
Table 59: Late-phase pipeline products in development for Crohn’s disease
Table 60: Remicade drug profile
Table 61: Remicade pivotal trial data in adult Crohn’s disease
Table 62: Remicade pivotal trial data in pediatric Crohn’s disease
Table 63: Cx601 drug profile
Table 64: Cx601 Phase III trials in Crohn’s disease
Table 65: Cx601 Phase I/II trials in Crohn’s disease
Table 66: Etrolizumab drug profile
Table 67: Ongoing pivotal trials for etrolizumab in Crohn’s disease
Table 68: Other late-phase trials for etrolizumab in Crohn’s disease
Table 69: Filgotinib drug profile
Table 70: Ongoing pivotal Phase III trials of filgotinib in Crohn’s disease
Table 71: Phase II trial data of filgotinib in Crohn’s disease
Table 72: Mongersen drug profile
Table 73: Pivotal trials for mongersen in Crohn’s disease
Table 74: Other ongoing Phase III trials for mongersen in Crohn’s disease
Table 75: Phase II trial data for mongersen in Crohn’s disease
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll